CClinicalTrials.gg
Sign In
RecruitingNCT07143110LUNG-ROLLUpdated Sep 3, 2026

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

An observational study in Lung Neoplasms, sponsored by AstraZeneca. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AstraZeneca · Observational

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
60,000
Ages
18 Years to 130 Years
Sex
All
01

Study summary

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

02

Conditions studied

  • Lung Neoplasms

Browse trials for

Keywords

  • Lung Neoplasms
  • Non-Small-Cell Lung
  • Small Cell Lung
  • Epidemiology
  • Treatment Patterns
  • Real-World
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's planned enrollment of 60,000 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population will comprise patients with lung cancer diagnosed after January 1, 2018 in the administrative databases for Alberta and Ontario.

Inclusion criteria

  • Patients with lung cancer between January 1, 2018 and end of the Selection Period.
  • Patient is 18 years of age or older on diagnosis date.
  • Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
  • Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
  • Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
  • Non-Ontario or non-Alberta resident on diagnosis date.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
60,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
06

What researchers measure

Primary outcomes

  1. Treatment patterns

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Incidence and prevalence

    Time frame: Through study completion, an average of 1 year

  2. Baseline demographic and clinical characteristics

    Time frame: Through study completion, an average of 1 year

  3. Overall survival

    Time frame: Through study completion, an average of 6 months

  4. Time to/on therapy

    Time frame: Through study completion, an average of 6 months

  5. Attrition rates

    Time frame: Through study completion, an average of 1 year

  6. Healthcare resource utilization (HCRU)

    Time frame: Through study completion, an average of 1 year

  7. Direct healthcare costs

    Time frame: Through study completion, an average of 1 year

07

Study locations

2 of 2 sites recruiting
  • Research Site
    Calgary, Alberta T2N1N4, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5T3M6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143110
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 20, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

AstraZeneca

Start the discussion